1. From the New Editor-In-Chief

   • Kenneth I. Kaitin

   OriginalPaper 31 December 2002 Pages: 1 - 1

2. The Impact of Sloppy Study Conduct on Noninferiority Studies

   • Armin Koch
   • Joachim Röhmel

   OriginalPaper 31 December 2002 Pages: 3 - 6

3. Response from the Original Author

   • Christy Chuang-Stein

   OriginalPaper 31 December 2002 Pages: 7 - 7

4. Designing Group Sequential Trials with Survival Endpoints

   • John Lawrence

   OriginalPaper 31 December 2002 Pages: 9 - 15

5. Compliance of Clinical Trial Consent Forms with International Guidelines: Analysis of Deficiencies

   • Yeong-Liang Lin
   • Chia-Hsin Huang
   • Bey-Liing Mau

   OriginalPaper 31 December 2002 Pages: 17 - 19

6. Adolescent Female Assent in Clinical Trials: A Model Assent Process

   • Debra Mattison
   • Terry M. VandenBosch
   • Becky Ward

   OriginalPaper 31 December 2002 Pages: 21 - 30

7. Current Status of Clinical Trials in Kenya

   • Ebi Kimanani

   OriginalPaper 31 December 2002 Pages: 31 - 39

8. Ethical Considerations in Clinical Trials in Asia

   • Noritoshi Tanida

   OriginalPaper 31 December 2002 Pages: 41 - 49

9. Working with Regulations in Foreign Countries, with Emphasis on Good Manufacturing Practice for Herbal Medicines

   • Willem K. Scholten

   OriginalPaper 31 December 2002 Pages: 51 - 55

10. The Pharmacokinetic/Pharmacodynamic Research Tool (Presto): An Advanced Concept for Rational Drug Development

    • Gernot Göller
    • Wolfgang Mück
    • Hans Poland

    OriginalPaper 31 December 2002 Pages: 57 - 66

11. Designing Success into Outsourced Pharmaceutical Projects at the Proposal Stage

    • Martin H. Joyce

    OriginalPaper 31 December 2002 Pages: 67 - 76

12. Strategic Outsourcing with Contract Research Organizations: Targeting Corporate Goals

    • Barbara Grady Rainville

    OriginalPaper 31 December 2002 Pages: 77 - 81

13. Pharmacogenetic Research: Perceptions of Informed Consent

    • Elizabeth C. McPherson
    • Susan C. Ray
    • Penelope K. Manasco

    OriginalPaper 31 December 2002 Pages: 83 - 93

14. The Value of Backup Compounds to Drug Development Programs

    • David A. Stock
    • Perry B. Molinoff

    OriginalPaper 31 December 2002 Pages: 95 - 113

15. Statistical Techniques to Detect Fraud and Other Data Irregularities in Clinical Questionnaire Data

    • Rosemary N. Taylor
    • Damian J. McEntegart
    • Eleanor C. Stillman

    OriginalPaper 31 December 2002 Pages: 115 - 125

16. Integrated Summaries and Meta-Analyses un Clinical Drug Development

    • Jürgen Kübler
    • Thomas R. Weihrauch

    OriginalPaper 31 December 2002 Pages: 127 - 133

17. Deming Principles Applied to Processing Data from Case Report Forms

    • David Salsburg

    OriginalPaper 31 December 2002 Pages: 135 - 141

18. A Fully Bayesian Approach to Calculating Sample Sizes for Clinical Trials with Binary Responses

    • Hamid Pezeshk
    • John Gittins

    OriginalPaper 31 December 2002 Pages: 143 - 150

19. Analysis of Combination Trials With No Placebo Arm

    • John Lawrence

    OriginalPaper 31 December 2002 Pages: 151 - 156

20. Analysis of Drug Safety Data From Clinical Trials

    • Andrzej Czarnecki
    • Katarzyna Zalewska

    OriginalPaper 31 December 2002 Pages: 157 - 162

21. The Value of the Certificate of Pharmaceutical Product in Registration of Medicinal Products

    • Alistair Davidson
    • Anthony J. Grace
    • Colin Vickers

    OriginalPaper 31 December 2002 Pages: 163 - 167

22. Streamlining the Research and Development Pipeline by Coupling of Information Technology and Biology

    • Hans F. Meyer

    OriginalPaper 31 December 2002 Pages: 169 - 178

23. Influences on Consumer Adoption of Herbal Therapies

    • Michael Ritho
    • Teresa B. Klepser
    • William R. Doucette

    OriginalPaper 31 December 2002 Pages: 179 - 186

24. Differences in Reading Level and Commercial Information Content in Pharmacy-Provided Health Information Printouts

    • Philip D. Rolland

    OriginalPaper 31 December 2002 Pages: 187 - 192

25. Pharmacy Students’ Attitudes Regarding a Web-Based Guide to Drug Information

    • Robert H. Schrimsher
    • Stephanie Gooch Wright

    OriginalPaper 31 December 2002 Pages: 193 - 200

26. Impact of Benefit Messages in Patient Package Inserts on Subjective Drug Perception

    • R. H. Vander Stichele
    • A. Vandierendonck
    • J. Lammertyn

    OriginalPaper 31 December 2002 Pages: 201 - 208

27. Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process

    • Olivier Chassany
    • Pierre Sagnier
    • For the European Regulatory Issues on Quality of Life Assessment Group

    OriginalPaper 31 December 2002 Pages: 209 - 238

28. Pharmacoeconomics and Outcomes Research—Is Intersectoral Collaboration Possible?

    • Devidas Menon
    • Joseph Gebran

    OriginalPaper 31 December 2002 Pages: 239 - 244